DNA Replication System from Pseudomonas aeruginosa

Information

  • Research Project
  • 6444461
  • ApplicationId
    6444461
  • Core Project Number
    R43GM064854
  • Full Project Number
    1R43GM064854-01
  • Serial Number
    64854
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/1/2002 - 23 years ago
  • Project End Date
    1/31/2003 - 22 years ago
  • Program Officer Name
    KORPELA, JUKKA K.
  • Budget Start Date
    2/1/2002 - 23 years ago
  • Budget End Date
    1/31/2003 - 22 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    1/21/2002 - 23 years ago
Organizations

DNA Replication System from Pseudomonas aeruginosa

DESCRIPTION (provided by applicant): The ongoing emergence of drug-resistant bacteria is rapidly reducing the efficacy of existing antibiotics leading to increased mortality, morbidity and public health burden due to bacterial infections. Since most drugs in late-stage clinical development are analogs of existing drugs to which resistance is expected to develop rapidly, there is an acute need for novel, mechanistically distinct antibacterials. To date, none of the antibacterials target any of the central components of the DNA replication system of bacteria. The overall aim of this project is to assemble a minimal DNA replication system from Pseudomonas aeruginosa, a clinically important pathogen in which the emergence of multidrug resistance is beginning to limit treatment options. We anticipate that 5 subunits will be minimally required to reconstitute the replicative polymerase capable of rapid and processive DNA synthesis: DnaE (DNA polymerase III subunit), DnaN (sliding clamp processivity factor), DnaX (clamp loader ATPase), HoIA and HoIB (accessory subunits of the clamp loader complex). All of these genes are apparent in the recently completed Pseudomonas aeruginosa genome. We plan to clone, express and purity these five proteins and use them to reconstitute a functional DNA replicase. This multiprotein assembly will then be used in high-throughput screens to identify new drug candidates that inhibit this and other bacterial replication systems. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    REPLIDYNE, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    LOUISVILLE
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    80027
  • Organization District
    UNITED STATES